Search company, investor...

Founded Year

2015

Stage

Series C - II | Alive

Total Raised

$188.5M

Last Raised

$25M | 1 yr ago

About Ribon Therapeutics

Ribon Therapeutics operates as a clinical-stage biotechnology company. It develops therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease. It specializes in the development and discovery of mono adenosine diphosphate (ADP)-ribose polymerase (monoPARP) inhibitors to block cancer cells' fundamental ability to survive under stress. The company was founded in 2015 and is based in Cambridge, Massachusetts.

Headquarters Location

35 Cambridgepark Drive Suite 300

Cambridge, Massachusetts, 02140,

United States

617-914-8700

Loading...

Loading...

Ribon Therapeutics Patents

Ribon Therapeutics has filed 19 patents.

The 3 most popular patent topics include:

  • transcription factors
  • monoclonal antibodies
  • proteins
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/29/2020

7/4/2023

Experimental cancer drugs, Monoclonal antibodies, Small nuclear RNA, Transcription factors, Proteins

Grant

Application Date

10/29/2020

Grant Date

7/4/2023

Title

Related Topics

Experimental cancer drugs, Monoclonal antibodies, Small nuclear RNA, Transcription factors, Proteins

Status

Grant

Latest Ribon Therapeutics News

Atamparib by Ribon Therapeutics for Breast Cancer: Likelihood of Approval

Oct 27, 2023

Brought to you by Atamparib is under clinical development by Ribon Therapeutics and currently in Phase II for Breast Cancer. According to GlobalData, Phase II drugs for Breast Cancer have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Atamparib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here. Smarter leaders trust GlobalData GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Atamparib overview Atamparib (RBN-2397) is under development for the treatment of advanced squamous non-small cell lung carcinoma, squamous cell carcinoma of the lung, mantle cell lymphoma, HER2 negative breast cancer, head and neck squamous cell carcinoma and other solid tumors. It is administered by oral route as tablet formulation. The drug candidate is a new chemical entity. The drug candidate acts by targeting monoPARPs (poly ADP-ribose polymerases) PARP7. Ribon Therapeutics overview Ribon Therapeutics is a biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions. The company leverages a chemical biology approach and its proprietary discovery platform for building a pipeline of small molecule inhibitors to numerous NAD+ utilizing enzymes includes monoPARPs, which have applications across multiple therapeutic areas. Its lead program is developing PARP7 inhibitors for the treatment of cancer. Ribon Therapeutics explores novel areas of disease biology and enzyme families for drug discovery and development of new treatments for patients with high unmet needs. The company is funded by including The Column Group, life science investors, U.S. Venture Partners, Deerfield Management and Osage University Partners. Ribon Therapeutics is headquartered in Cambridge, Massachusetts, the US. For a complete picture of Atamparib’s drug-specific PTSR and LoA scores, buy the report here. This content was updated on 9 October 2023 Sign up for our daily news round-up! Give your business an edge with our leading industry insights.

Ribon Therapeutics Frequently Asked Questions (FAQ)

  • When was Ribon Therapeutics founded?

    Ribon Therapeutics was founded in 2015.

  • Where is Ribon Therapeutics's headquarters?

    Ribon Therapeutics's headquarters is located at 35 Cambridgepark Drive, Cambridge.

  • What is Ribon Therapeutics's latest funding round?

    Ribon Therapeutics's latest funding round is Series C - II.

  • How much did Ribon Therapeutics raise?

    Ribon Therapeutics raised a total of $188.5M.

  • Who are the investors of Ribon Therapeutics?

    Investors of Ribon Therapeutics include The Column Group, U.S. Venture Partners, Peregrine Ventures, Novartis Venture Funds, Pfizer and 15 more.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.